{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023218","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.616554+00:00","generated_at":"2026-06-22T03:15:15.101656+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Assembly Biosciences Q3 net loss $23.1M; CEO retirement, new pipeline programs announced","bullets":["Net loss of $23.1M ($0.48 per share) vs $18.8M ($0.41) in Q3 2021.","Cash and marketable securities $108.7M; projected to fund operations into H1 2024.","R&D expenses $18.1M, down slightly from $18.5M YoY.","CEO John McHutchison to retire end of 2022; President Jason Okazaki named successor.","Phase 1a trial of next-gen core inhibitor ABI-4334 initiated; new HSV-2 and herpesvirus programs introduced."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023218","json":"https://secwatch.observer/filing/0000950170-22-023218.json","markdown":"https://secwatch.observer/filing/0000950170-22-023218.md","text":"https://secwatch.observer/filing/0000950170-22-023218.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017022023218/0000950170-22-023218-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017022023218/asmb-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:15:15.101656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7f5fd209d01ae961a534e5b39f9a3bb808a7e8e","claim":"ASSEMBLY BIOSCIENCES, INC. reported the third quarter ended September 30, 2022 results: net income Net loss attributable to common stockholders was $23.1 million, or $0.48 per basic and diluted share, EPS $0.48 per basic and diluted share.","evidence_excerpt":"Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000095017022023218/0000950170-22-023218-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss attributable to common stockholders was $23.1 million, or $0.48 per basic and diluted share"},{"label":"EPS","value":"$0.48 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}